FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / BMC Vet Res / Differential modulation of inflammatory cytokines by recombi...
BMC veterinary research2024; 20(1); 546; doi: 10.1186/s12917-024-04403-2

Differential modulation of inflammatory cytokines by recombinant IL-10 in IL-1β and TNF-α ̶ stimulated equine chondrocytes and synoviocytes: impact of washing and timing on cytokine responses.

Abstract: Osteoarthritis (OA) remains a challenging joint disorder necessitating effective anti-inflammatory interventions. In this study, our primary objective was to establish an in vitro protocol that replicates the clinical investigation of anti-inflammatory drugs intended for OA management. Focusing on recombinant IL-10 (r.IL-10) as a potential anti-inflammatory treatment, we designed and implemented two distinct protocols to evaluate the efficacy of r.IL-10 in modulating chondrocyte and synoviocyte inflammation.The experimental design involved sequential stimulation with IL-1β and TNF-α for 24 h, followed by washing (model 1) or not washing (model 2) the cells before r.IL-10 treatment. Samples were collected after 6-24 h of treatment. Cellular responses were evaluated by quantifying gene expression and synthesis of key inflammatory cytokines and proteases.The expression and synthesis of inflammatory cytokines and proteases was significantly affected by washing and treatment time. The expression of IL-1β, TNF-α, IL-8, MMP-13, and ADAMTS5 were effectively reduced in r.IL-10-treated chondrocytes and synoviocytes in model 2 after 24 h, particularly at concentrations of 10 and 20 ng/mL. r.IL-10 treatment significantly increased IL-6 gene expression in chondrocytes at all time points. However, in synoviocytes, IL-6 expression was significantly lower in model 2 after 24 h of r.IL-10 treatment. r.IL-10 treatment significantly decreased IL-1β and TNF-α content in synoviocyte supernatants, particularly in model 2 at concentrations of 10 and 20 ng/mL after 6 and 24 h. r.IL-10 treatment in chondrocytes led to a significant decrease in IL-1β supernatant concentrations in model 2 after 24 h only.This study demonstrated that r.IL-10 treatment effectively reduces key inflammatory markers and matrix metalloproteinase activity in both chondrocytes and synoviocytes, particularly in model 2 where cells were not washed prior to treatment. These findings highlight r.IL-10's potential as a robust anti-inflammatory agent for OA management and suggest its critical role in developing effective therapeutic strategies for OA.
© 2024. The Author(s).
Get Full Text
Publication Date: 2024-12-02 PubMed ID: 39623412PubMed Central: PMC11610082DOI: 10.1186/s12917-024-04403-2Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research investigated the modulatory effects of a potential anti-inflammatory treatment, r.IL-10, on inflammation caused by osteoarthritis (OA) in connective tissues. Two protocols were used; one involving washing cells prior to treatment, and the other without washing. The study found that r.IL-10 was effective in reducing inflammation and proteases involved in tissue breakdown, particularly when cells were not washed prior to treatment.

Research Aim and Methodology

  • The study aimed to establish an in vitro protocol that could simulate the clinical process of investigating anti-inflammatory drugs for OA treatment. The focus was on the differential effects of the recombinant IL-10 (r.IL-10) as an anti-inflammatory treatment.
  • The investigation involved two models: In model 1, cells were sequentially stimulated with IL-1β and TNF-α, two molecules involved in inflammatory response, for 24 hours. After this, the cells were washed before application of r.IL-10 treatment. In model 2, the same process was followed but the cells were not washed before r.IL-10 treatment.
  • Following r.IL-10 treatment, samples were collected every 6-24 hours. The cell responses to the treatment were evaluated by measuring the expression of key inflammatory genes and the production of inflammatory cytokines and proteases.

Key Findings

  • The results showed that washing and treatment time significantly affected the expression and production of inflammatory cytokines and proteases.
  • The expression of IL-1β, TNF-α, IL-8, MMP-13, and ADAMTS5 – molecules that trigger inflammation and tissue breakdown – were effectively reduced with the r.IL-10 treatment, particularly after 24 hours in model 2.
  • r.IL-10 increased IL-6 gene expression in chondrocytes at all time points which may denote an anti-inflammatory response, but decreased IL-6 expression in synoviocytes specifically in model 2 after 24h of treatment.
  • r.IL-10 treatment led to a significant decrease in IL-1β and TNF-α content in synoviocytes, particularly in model 2 at concentrations of 10 and 20 ng/mL after 6 and 24h, indicating its anti-inflammatory effect.
  • r.IL-10 treatment in chondrocytes led to a significant decrease in IL-1β supernatant concentrations in model 2 after 24h.

Conclusion

  • The study concluded that r.IL-10 treatment can effectively reduce key inflammatory markers and matrix metalloproteinase activity. Precisely, when cells were not washed before treatment (model 2), r.IL-10 treatment had superior anti-inflammatory effects, demonstrating possible therapeutic potential for OA management.

Cite This Article

APA
Elkhenany HA, Linardi RL, Ortved KF. (2024). Differential modulation of inflammatory cytokines by recombinant IL-10 in IL-1β and TNF-α ̶ stimulated equine chondrocytes and synoviocytes: impact of washing and timing on cytokine responses. BMC Vet Res, 20(1), 546. https://doi.org/10.1186/s12917-024-04403-2

Publication

BMC veterinary research
ISSN: 1746-6148
NlmUniqueID: 101249759
Country: England
Language: English
Volume: 20
Issue: 1
Pages: 546
PII: 546

Researcher Affiliations

Elkhenany, Hoda A
  • Department of Clinical Studies-New Bolton Center, University of Pennsylvania, 382 West Street Road, Kennett Square, PA, 19348, USA.
  • Department of Surgery, Faculty of Veterinary Medicine, Alexandria University, Alexandria, Egypt.
Linardi, Renata L
  • Department of Clinical Studies-New Bolton Center, University of Pennsylvania, 382 West Street Road, Kennett Square, PA, 19348, USA.
Ortved, Kyla F
  • Department of Clinical Studies-New Bolton Center, University of Pennsylvania, 382 West Street Road, Kennett Square, PA, 19348, USA. kortved@vet.upenn.edu.

MeSH Terms

  • Animals
  • Chondrocytes / drug effects
  • Chondrocytes / metabolism
  • Horses
  • Interleukin-1beta / metabolism
  • Interleukin-1beta / pharmacology
  • Synoviocytes / drug effects
  • Synoviocytes / metabolism
  • Tumor Necrosis Factor-alpha / metabolism
  • Tumor Necrosis Factor-alpha / genetics
  • Tumor Necrosis Factor-alpha / pharmacology
  • Interleukin-10 / metabolism
  • Interleukin-10 / genetics
  • Cytokines / metabolism
  • Cytokines / genetics
  • Recombinant Proteins / pharmacology
  • Cells, Cultured
  • Anti-Inflammatory Agents / pharmacology

Conflict of Interest Statement

Declarations. Ethics approval and consent to participate: The study involving equine cartilage and synovium tissue collection was approved by the Institutional Animal Care and Use Committee (IACUC), the University of Pennsylvania (Animal Use Protocol No. #806625). Consent for publication: All authors have read and agreed to the published version of the manuscript. Competing interests: The authors declare no competing interests.

References

This article includes 43 references
  1. Krasnokutsky S. Current concepts in the pathogenesis of osteoarthritis.. Osteoarthr Cartil 2008;16:S1–3.
    pubmed: 18723377
  2. Castrogiovanni P. Moderate physical activity as a Prevention Method for knee osteoarthritis and the role of synoviocytes as Biological Key.. Int J Mol Sci 2019;20(3):511.
    pmc: PMC6387266pubmed: 30691048
  3. Keystone E, Wherry J, Grint P. IL-10 AS A THERAPEUTIC STRATEGY IN THE TREATMENT OF RHEUMATOID ARTHRITIS.. Rheumatic Disease Clin North Am 1998;24(3):629–39.
    pubmed: 9710891
  4. Takimoto CH, Wick M. CHAPTER 29 - Preclinical Drug Development. Principles of Clinical Pharmacology (Second Edition) 2007, Academic Press: Burlington. pp. 449–462.
  5. Kuppa SS. Polynucleotides suppress inflammation and stimulate Matrix Synthesis in an in vitro cell-based Osteoarthritis Model.. Int J Mol Sci 2023. 24(15).
    pmc: PMC10418450pubmed: 37569659
  6. Salgado C. In vitro anti-inflammatory activity in arthritic synoviocytes of A. brachypoda root extracts and its unusual dimeric flavonoids.. Molecules 2020;25(21):5219.
    pmc: PMC7665123pubmed: 33182470
  7. Marrero-Berrios I. In vitro inflammatory multi-cellular model of osteoarthritis.. Osteoarthr Cartil Open 2024;6(1):100432.
    pmc: PMC10823137pubmed: 38288345
  8. Samavedi S. A three-dimensional chondrocyte-macrophage coculture system to probe inflammation in experimental osteoarthritis.. Tissue Eng Part A 2017;23(3–4):101–14.
    pmc: PMC5312455pubmed: 27736317
  9. Kurz B, Steinhagen J, Schünke M. Articular chondrocytes and synoviocytes in a co-culture system: influence on reactive oxygen species-induced cytotoxicity and lipid peroxidation.. Cell Tissue Res 1999;296(3):555–63.
    pubmed: 10370143
  10. Bhattacharjee A, Katti DS. A human osteoarthritis mimicking goat cartilage explant-based disease model for drug screening.. ALTEX - Altern Anim Experimentation 2022;39(3):427–41.
    pubmed: 35258089
  11. Goldring MB, Otero M. Inflammation in osteoarthritis.. Curr Opin Rheumatol 2011;23(5):471–8.
    pmc: PMC3937875pubmed: 21788902
  12. Xue J. Tumor necrosis factor-α induces ADAMTS-4 expression in human osteoarthritis chondrocytes.. Mol Med Rep 2013;8(6):1755–60.
    pubmed: 24126638
  13. Nixon AJ, Lust G, Vernier-Singer M. Isolation, propagation, and cryopreservation of equine articular chondrocytes.. Am J Vet Res 1992;53(12):2364–70.
    pubmed: 1476323
  14. Haupt JL. Dual transduction of insulin-like growth factor‐I and interleukin‐l receptor antagonist protein controls cartilage degradation in an osteoarthritic culture model.. J Orthop Res 2005;23(1):118–26.
    pubmed: 15607883
  15. Linardi RL. The effect of autologous protein solution on the inflammatory cascade in stimulated equine chondrocytes.. Front Veterinary Sci 2019;6:64.
    pmc: PMC6414419pubmed: 30895181
  16. Nixon A. Gene-mediated restoration of cartilage matrix by combination insulin-like growth factor-I/interleukin-1 receptor antagonist therapy.. Gene Ther 2005;12(2):177–86.
    pubmed: 15578043
  17. Tsuchida AI. Interleukin-6 is elevated in synovial fluid of patients with focal cartilage defects and stimulates cartilage matrix production in an in vitro regeneration model.. Arthritis research & therapy 2012;14:1–12.
    pmc: PMC3674617pubmed: 23206933
  18. Fu X. Assessment of the efficacy of joint lavage in rabbits with osteoarthritis of the knee.. J Orthop Res 2009;27(1):91–6.
    pubmed: 18655133
  19. Wu C-C. Evaluation of the post-treatment anti-inflammatory capacity of osteoarthritic chondrocytes: an in vitro study using baicalein.. Regenerative Therapy 2020;14:177–83.
    pmc: PMC7042419pubmed: 32128354
  20. Kessler B. Interleukin 10 inhibits pro-inflammatory cytokine responses and killing of Burkholderia pseudomallei.. Sci Rep 2017;7(1):42791.
    pmc: PMC5316963pubmed: 28216665
  21. Ortved KF. AAV-mediated overexpression of IL-10 mitigates the inflammatory cascade in stimulated equine chondrocyte pellets.. Curr Gene Ther 2018;18(3):171–9.
    pubmed: 29749312
  22. Moss KL. Sustained interleukin-10 transgene expression following intra-articular AAV5-IL-10 administration to horses.. Hum Gene Ther 2020;31(1–2):110–8.
    pmc: PMC7872004pubmed: 31773987
  23. Iannone F. Interleukin-10 and interleukin-10 receptor in human osteoarthritic and healthy chondrocytes.. Clin Exp Rheumatol 2001;19(2):139–45.
    pubmed: 11332442
  24. Pujol J. Role of cytokines in osteoarthritis: comparative effects of interleukin 1 and transforming growth factor-beta on cultured rabbit articular chondrocytes.. J Rheumatol Suppl 1991;27:76–9.
    pubmed: 2027137
  25. Pujol J-P. Interleukin-1 and transforming growth factor-ß 1 as crucial factors in osteoarthritic cartilage metabolism.. Connect Tissue Res 2008;49(3–4):293–7.
    pubmed: 18661363
  26. Behrendt P. IL-10 reduces apoptosis and extracellular matrix degradation after injurious compression of mature articular cartilage.. Osteoarthr Cartil 2016;24(11):1981–8.
    pubmed: 27349464
  27. Driessler F. Molecular mechanisms of interleukin-10-mediated inhibition of NF-κ B activity: a role for p50.. Clin Experimental Immunol 2004;135(1):64–73.
    pmc: PMC1808913pubmed: 14678266
  28. Mrosewski I. Regulation of osteoarthritis-associated key mediators by TNFα and IL-10: effects of IL-10 overexpression in human synovial fibroblasts and a synovial cell line.. Cell Tissue Res 2014;357(1):207–23.
    pubmed: 24816983
  29. Keller LE. Regulatory T cells provide chondroprotection through increased TIMP1, IL-10 and IL-4, but cannot mitigate the catabolic effects of IL-1β and IL-6 in a tri-culture model of osteoarthritis.. Osteoarthr Cartil Open 2021;3(3):100193.
    pmc: PMC9718146pubmed: 36474817
  30. Chou C-H. Synovial cell cross-talk with cartilage plays a major role in the pathogenesis of osteoarthritis.. Sci Rep 2020;10(1):10868.
    pmc: PMC7331607pubmed: 32616761
  31. Cameron AD. Adeno-Associated virus-mediated overexpression of Interleukin-10 affects the Immunomodulatory properties of equine bone marrow-derived mesenchymal stem cells.. Hum Gene Ther 2021;32(17–18):907–18.
    pubmed: 33843261
  32. Scheller J. The pro-and anti-inflammatory properties of the cytokine interleukin-6.. Biochim et Biophys Acta (BBA)-Molecular Cell Res 2011;1813(5):878–88.
    pubmed: 21296109
  33. Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging.. Cell 2006;127(2):265–75.
    pubmed: 17055429
  34. Collado M, Serrano M. Senescence in tumours: evidence from mice and humans.. Nat Rev Cancer 2010;10(1):51–7.
    pmc: PMC3672965pubmed: 20029423
  35. Campisi J, d’Adda Di Fagagna. Cellular senescence: when bad things happen to good cells.. Nat Rev Mol Cell Biol 2007;8(9):729–40.
    pubmed: 17667954
  36. Yu LK. Coculture with interleukin-10 overexpressed chondrocytes: a cell therapy model to ameliorate the post-traumatic osteoarthritis development.. J Biol Regul Homeost Agents 2021;35(2):593–603.
    pubmed: 33890435
  37. Alaaeddine N. Inhibition of tumor necrosis factor α–induced prostaglandin E2 production by the antiinflammatory cytokines interleukin-4, interleukin-10, and interleukin-13 in osteoarthritic synovial fibroblasts: distinct targeting in the signaling pathways.. Arthritis & Rheumatism 1999;42(4):710–8.
    pubmed: 10211885
  38. Manferdini C. Lack of anti-inflammatory and anti-catabolic effects on basal inflamed osteoarthritic chondrocytes or synoviocytes by adipose stem cell-conditioned medium.. Osteoarthr Cartil 2015;23(11):2045–57.
    pubmed: 26521751
  39. Sugimoto Y, Narumiya S. Prostaglandin E receptors.. J Biol Chem 2007;282(16):11613–7.
    pubmed: 17329241
  40. Pan Y. Myeloid cyclooxygenase-2/prostaglandin E2/E-type prostanoid receptor 4 promotes transcription factor MafB-dependent inflammatory resolution in acute kidney injury.. Kidney Int 2022;101(1):79–91.
    pmc: PMC8741730pubmed: 34774558
  41. Scher JU, Pillinger MH. The anti-inflammatory effects of prostaglandins.. J Investig Med 2009;57(6):703–8.
    pubmed: 19240648
  42. Xu XJ. Prostaglandin E2 suppresses lipopolysaccharide-stimulated IFN-beta production.. J Immunol 2008;180(4):2125–31.
    pmc: PMC2396778pubmed: 18250418
  43. Kunkel SL. Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression.. J Biol Chem 1988;263(11):5380–4.
    pubmed: 3162731

Citations

This article has been cited 0 times.
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.